Q3 2017 Earnings Forecast for Valeant Pharmaceuticals Intl Inc Issued By Jefferies Group (TSE:VRX)

Valeant Pharmaceuticals Intl Inc (TSE:VRX) (NYSE:VRX) – Research analysts at Jefferies Group reduced their Q3 2017 earnings per share estimates for shares of Valeant Pharmaceuticals Intl in a report released on Wednesday. Jefferies Group analyst D. Steinberg now anticipates that the specialty pharmaceutical company will post earnings per share of $1.05 for the quarter, down from their prior forecast of $1.38. Jefferies Group also issued estimates for Valeant Pharmaceuticals Intl’s Q4 2017 earnings at $1.01 EPS, FY2017 earnings at $4.37 EPS, FY2018 earnings at $4.22 EPS, FY2019 earnings at $4.88 EPS, FY2020 earnings at $5.69 EPS and FY2021 earnings at $6.47 EPS.

COPYRIGHT VIOLATION WARNING: This piece of content was first reported by Community Financial News and is the sole property of of Community Financial News. If you are reading this piece of content on another publication, it was illegally stolen and reposted in violation of U.S. and international trademark & copyright legislation. The correct version of this piece of content can be viewed at https://www.com-unik.info/2017/08/12/q3-2017-earnings-forecast-for-valeant-pharmaceuticals-intl-inc-issued-by-jefferies-group-tsevrx.html.

VRX has been the subject of a number of other research reports. Royal Bank Of Canada reiterated an “outperform” rating on shares of Valeant Pharmaceuticals Intl in a report on Tuesday, April 18th. TD Securities boosted their price target on Valeant Pharmaceuticals Intl to C$26.00 and gave the company a “hold” rating in a report on Wednesday, July 12th. Scotiabank lowered their price target on Valeant Pharmaceuticals Intl to C$16.00 and set a “sector perform” rating for the company in a report on Wednesday, April 26th. Finally, Cantor Fitzgerald reissued an “overweight” rating on shares of Valeant Pharmaceuticals Intl in a research note on Thursday, June 29th. Four investment analysts have rated the stock with a hold rating and one has assigned a buy rating to the company. The company currently has an average rating of “Hold” and a consensus price target of C$23.33.

Valeant Pharmaceuticals Intl (VRX) opened at 17.59 on Friday. The stock has a 50 day moving average price of $21.16 and a 200 day moving average price of $17.59. Valeant Pharmaceuticals Intl has a 12 month low of $11.20 and a 12 month high of $42.25. The company’s market cap is $6.12 billion.

In related news, Director John Paulson sold 24,700 shares of the business’s stock in a transaction that occurred on Wednesday, August 9th. The shares were sold at an average price of C$14.66, for a total value of C$362,102.00.

About Valeant Pharmaceuticals Intl

Valeant Pharmaceuticals International, Inc operates as a pharmaceutical and medical device company worldwide. It operates in three segments: Bausch + Lomb/International, Branded Rx, and U.S. Diversified Products. The company offers Lotemax gel for the treatment of inflammation and pain following ocular surgery; Ocuvite, a lutein eye vitamin and mineral supplement; PreserVision, an antioxidant eye vitamin and mineral supplement; ReNu Multiplus products; Biotrue multi-purpose solution for healthy contact lens wear; Artelac to treat dry eyes; Boston, a cleansing solution for gas permeable contact lenses; and Bedoyecta, a vitamin B complex.

What are top analysts saying about Valeant Pharmaceuticals Intl Inc? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Valeant Pharmaceuticals Intl Inc and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit